Establishing a translational leader in precision medicine through knowledge transfer to develop point-of-care drug monitoring technologies

通过知识转移开发即时药物监测技术，建立精准医学领域的转化领导者

• 批准号: 75899
• 金额: $ 9.43万
• 依托单位: NEWCASTLE UNIVERSITY
• 依托单位国家: 英国
• 项目类别: Study
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=75899
• 关键词: Establishing; translational; leader; precision; medicine

This bi-directional collaboration, offers a secondee from Newcastle University an opportunity to work with an innovative biomedical start-up, Vesynta Ltd, for the development of a novel companion monitoring tool, enabling doctors to accurately monitor anti-cancer drug-exposure in children. It will provide an immediate, simple to use, bedside measurement of medicine concentration in the blood: an essential improvement in care.Cancer is the leading cause of death in children aged 0-14 years. Giving the safest and most effective dose of anti-cancer drugs to children is a clinical challenge for doctors. They currently calculate the amount of anti-cancer drugs the patient will have using their height and weight as a guide. However, as children's bodies all process medicines very differently, this method is not accurate and leads to marked differences in drug exposure between patients. As a result, ~40% of children suffer from medicine related side-effects which reduces their quality of life and costs healthcare providers.To give the correct amount of treatment, doctors need technologies which provide real-time and accurate patient drug exposure data; yet, this information is rarely available and challenging tto obtain. Vesynta has developed a technology with promises to meet these criteria, however, it requires quality assurance over its technology, further design considerations to ensure it is suited for the end-user, and an expansion of the technology to co-medicines which are also given to children, to ensure maximum patient benefit.This project will leverage the secondee's skills in drug testing development, clinical pharmacology and problem-solving using analytical instruments, to validate the platform technology. In return, the secondee shall become a 'Translation and Innovation Lead' at Newcastle University, with skills exposure to human factors design, medical device regulation and health economics. The project shall build on the voiced needs of patients, parents and doctors, as captured from stakeholder engagement workshops designed by the secondee, who shall also support follow-up research plans through clinical trial design.This carefully planned research, will provide benefit to both secondee and host organisation, in terms of skills, knowledge and career porosity. The successful delivery of this project will propel the secondee in his professional ambitions and support Vesynta in accelerating their research and development activity. Crucially, facilitation of biomedical innovation will fast-track the implementation of personalised medicine in paediatric oncology, for the benefit to children and the wider healthcare sector.Update (Oct. 2022) - following discussion with our project manager (Liz Littlewood) we have a new secondee in place to take this project forward following staffing changes here at the university. The new secondee has a >90% match of the original learning outcomes and their role exactly aligns with the original proposals, due to similarity of the role the new individual holds within the host organization.

这种双向合作为纽卡斯尔大学的借调人员提供了与创新生物医学初创公司Vesynta Ltd合作的机会，以开发一种新型的伴侣监测工具，使医生能够准确监测儿童的抗癌药物暴露。它将提供一种即时、简单易用的床边血液药物浓度测量：这是护理的一个重要改进。癌症是0-14岁儿童死亡的主要原因。如何给儿童提供最安全、最有效剂量的抗癌药物，是医生面临的临床挑战。他们目前使用患者的身高和体重作为指导来计算抗癌药物的量。然而，由于儿童的身体对药物的处理方式非常不同，这种方法并不准确，导致患者之间的药物暴露存在显著差异。因此，约40%的儿童患有药物相关的副作用，这降低了他们的生活质量，并使医疗保健提供者付出代价。为了给予正确的治疗量，医生需要提供实时准确的患者药物暴露数据的技术;然而，这些信息很少可用，并且难以获得。Vesynta开发了一项技术，有望满足这些标准，但需要对其技术进行质量保证，进一步考虑设计以确保其适合最终用户，并将该技术扩展到儿童使用的联合药物，以确保患者受益最大化。该项目将利用借调人员在药物测试开发方面的技能，临床药理学和使用分析仪器解决问题，以验证平台技术。作为回报，借调人员将成为纽卡斯尔大学的“翻译和创新负责人”，掌握人为因素设计、医疗器械监管和卫生经济学方面的技能。该项目将建立在患者、家长和医生的需求基础上，这些需求是从借调人员设计的利益相关者参与研讨会中获得的，借调人员还将通过临床试验设计支持后续研究计划。这种精心策划的研究将在技能、知识和职业孔隙度方面为借调人员和东道国组织带来好处。该项目的成功交付将推动借调人员实现其职业抱负，并支持Vesynta加速其研发活动。至关重要的是，促进生物医学创新将快速跟踪个性化医疗在儿科肿瘤学的实施，以造福儿童和更广泛的医疗保健部门。更新（2022年10月）-在与我们的项目经理（Liz Littlewood）讨论后，我们有一个新的借调人员到位，以推动该项目在这里的大学人员变动后向前发展。新借调人员的学习成果与原来的学习成果有90%以上的匹配度，而且由于新借调人员在东道组织内的角色相似，他们的角色与原来的提议完全一致。